Aertgeerts J, Aussems J, Put H
Arzneimittelforschung. 1976;26(8):1617-8.
In a double blind fully randomised trial, three Belgian dermatologists independently treated 81 patients suffering from various eczematous skin disorders. After four weeks both the dermatologists and their patients assessed the results of a twice-daily topical application of an ointment containing 17 beta-hydroxy-4-estren-3-one-17-decanoate (nandrolone decanoate, Dexatopic) ointment or a reference ointment. Both the dermatologists' and the patients' assessments of the two preparations showed that there was no significant difference between the two treatments although Dexatopic did seem to have a more favourable profile in the "much improved" area. In the total score decrease, there was an indication that Dexatopic had a more favourable effect than the reference preparation.
在一项双盲完全随机试验中，三位比利时皮肤科医生独立治疗了81名患有各种湿疹性皮肤病的患者。四周后，皮肤科医生及其患者对每日两次局部使用含17β-羟基-4-雌甾烯-3-酮-17-癸酸酯（癸酸诺龙，德沙托皮克）软膏或对照软膏的结果进行了评估。皮肤科医生和患者对两种制剂的评估均显示，两种治疗方法之间无显著差异，尽管德沙托皮克在“改善明显”方面似乎有更有利的表现。在总分降低方面，有迹象表明德沙托皮克比对照制剂有更有利的效果。
